• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.72% Nasdaq Up1.68%

    More On SVFC



    News & Info


    Analyst Coverage



    IntelliCell BioSciences, Inc. (SVFC)

    -Other OTC
    0.00 0.00(0.00%) Feb 9
    ProfileGet Profile for:
    IntelliCell BioSciences, Inc.
    460 Park Avenue
    17th Floor
    New York, NY 10022
    United States - Map
    Phone: 212-249-3050
    Website: http://www.intellicellbiosciences.com

    Index Membership:N/A
    Full Time Employees:6

    Business Summary 

    IntelliCell BioSciences, Inc. operates as a regenerative medicine company in the United States. It develops and commercializes regenerative medicine using adult autologous stromal vascular fraction cells derived from the blood vessels in adipose tissue. The company’s products are intended to treat various clinical conditions, such as aesthetic conditions, orthopedic and sports injuries, and pain, as well as cardiac, gastrointestinal, periodontal, and autistic disorders. It also focuses on undertaking clinical studies in partnership with universities and hospitals for osteoarthritis, gum regeneration, non-healing diabetic ulcers, multiple sclerosis, cartilage regeneration, tendon repair, facial lines and wrinkles, chronic migraine headache, bone regeneration, and hair regeneration indications. In addition, the company is involved in sourcing, selling, and distributing laboratory equipment and supplies, which are used in tissue processing activities. It also licenses its products in Canada, Australia, New Zealand, and Thailand. The company has a collaboration agreement with Hielscher Ultrasonics to develop closed processing system for cell therapy manufacturing. IntelliCell BioSciences, Inc. is based in New York, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on IntelliCell BioSciences, Inc.

    Key Executives 
    Dr. Steven A. Victor M.D., 64
    Chairman and Chief Exec. Officer
    Mr. John Huber III,
    Interim Chief Financial Officer
    Mr. Leonard A. Mazur , 70
    Interim Chief Operating Officer, Director and Chairman of Compensation Committee
    Ms. Anna Rhodes ,
    Exec. VP of Operations
    Ms. Sarah R. Young ,
    Director of Quality Assurance
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders